Unique Attack Method for New Antibiotic
Researchers discovered manikomycin, a soil-derived peptide that attacks bacteria in a unique way to bypass existing antibiotic resistance.
Tag: MRSA and multidrug resistant bacteria
All
Latest
Unique Attack Method for New Antibiotic
Researchers discovered manikomycin, a soil-derived peptide that attacks bacteria in a unique way to bypass existing antibiotic resistance.
Read More
Microgravity Affects Bacteria-infecting Viruses
Aboard the International Space Station, bacteria-infecting viruses and their hosts accumulate distinctive mutations in near-weightlessness.
Read More
How Bacteria Hinder Wound Healing
Staphylococcus aureus (S. aureus) delays wound healing through a mechanism that suppresses skin cell metabolism needed for repair.
Read More
Sharp Rise in Drug-resistant Bacteria NDM-CRE
Between 2019 and 2023, NDM-CRE infections—which include pneumonia, bloodstream infections, urinary tract infections, and wound infections—surged by more than 460% in the United States.
Read More
Hospital Halts Outbreak of P. aeruginosa
UCLA Health detected and halted a rare strain of Pseudomonas aeruginosa that carries a gene called NDM-1, or New Delhi metallo-β-lactamase.
Read More
Modified Penicillin Activated by Green Light
Researchers using green light to activate penicillin say controlling drug activity with light will allow precise and safe treatment of localized infections.
Read More
New Therapy Benefitted Some Drug-resistant TB Patients
Some patients with pre-extensively drug-resistant TB benefitted from shorter, simpler regimens.
Read More
Cancer Patients Face Elevated Risk of Antimicrobial Resistant Superbugs
Cancer patients in both hospital and outpatient settings are at a substantially higher risk of developing antimicrobial resistant infections compared to all other non-cancer patients.
Read More
Nebulized Phage Therapy May Treat Antimicrobial Resistance in CF Patients
Phage therapy—the use of viruses, or phages, to target and kill bacteria—improved lung function and reduced sputum P. aeruginosa in patients with cystic fibrosis.
Read More
Prior Antibiotic Exposure Linked to Increased Hospital-Onset Antimicrobial Resistant Infections During Pandemic
During the COVID-19 pandemic, hospital-onset antimicrobial-resistant (AMR) infections increased by 6.5% and remained 11.6% above baseline by March 2022.
Read More
Sensors Detect Multidrug-resistant Bacteria
Scientists are developing sensor-based tests to quickly detect superbugs like K. pneumoniae, S. aureus, and P. aeruginosa.
Read More
Top 10 Patient Safety Threats
The ECRI’s annual list of patient safety threats includes healthcare-associated infections and medical misinformation, but it’s topped by a particular physician behavior towards patients and caregivers that can lead to a loss of trust.
Read More
Positive Results for Viromed VAP Therapy
Viromed Medical AG is reporting positive results for its PulmoPlas therapy in the treatment of ventilator-associated pneumonia (VAP) in intensive care unit patients.
Read More
Three New Ways To Treat Drug-Resistant Tuberculosis
An international clinical trial has found three new safe and effective drug regimens for tuberculosis that is resistant to rifampin, the most effective of the first-line antibiotics used to treat TB.
Read More
Hospital Stays Put Families at Risk of Superbug Infections, Study Finds
Family members of recently discharged patients face an increased risk of antibiotic-resistant infections, even if the patient was not diagnosed with the infection.
Read More
Baxter Expands US Pharma Portfolio
Baxter has expanded its US pharmaceuticals portfolio by launching five injectable drugs, including Vancomycin to treat infections of methicillin-resistant staphylococci.
Read More
US Hospitals Slow to Adopt Newer Antibiotics for Highly Resistant Infections
Hospitals still treated over 40% of patients battling highly resistant infections exclusively with the older, generic agents, an NIH study finds.
Read More
Liquid Crystal Nanoparticles Supercharge Antibiotics for Cystic Fibrosis
Researchers are developing liquid nanoparticles to bypass the barriers posed by thick mucus and frequent infections in cystic fibrosis lungs and prevent antimicrobial resistance.
Read More
Generative AI Model Designs New Superbug-fighting Antibiotics
Researchers have invented a new artificial intelligence model that can design billions of new antibiotic molecules that are inexpensive and easy to build in the laboratory.
Read More
AI Uncovers Promising Antibiotic to Fight Evasive Hospital Superbug
Scientists have used artificial intelligence to discover a new antibiotic that could be used to fight a deadly, drug-resistant pathogen that strikes vulnerable hospital patients.
Read More
FDA Approves Manufacturing Site for C. difficile Preventative Therapy
Recipharm’s Vowst therapy is approved to prevent reinfection of C. difficile, which can infect patients with cystic fibrosis and other chronic diseases.
Read More
Long-forgotten Antibiotic Effective Against Multidrug-resistant Bacteria
The discovery of nourseothricin in the 1940s generated high hopes for it as a powerful agent against Gram-negative bacteria, but its development was dropped after proving toxic to kidneys. However, researchers are now taking another look.
Read More
FDA-approved Tuberculosis Regimen May Not Work for TB Meningitis
A US FDA-approved antibiotic regimen for multidrug-resistant (MDR) tuberculosis (TB) may not work for TB meningitis.
Read More
Probiotic Significantly Reduced S. aureus Colonization
The probiotic Bacillus subtilis markedly reduced S. aureus colonization in trial participants without harming their gut microbiota.
Read More